SCHEMBL1121776

SCHEMBL1121776

COS(=O)(=O)CC1CN(C(c2ccccc2)c2ccccc2)C1.CS(=O)(=O)OCC1CN(C(=O)O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 5/20 0.41
SCN7A Q01118 1/20 0.41
SCN5A Q14524 1/20 0.41
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NPC1 O15118 1/20 0.35
SLC6A9 P48067 1/20 0.35
CYP3A4 P08684 4/20 0.35
CYP2D6 P10635 4/20 0.35
USP2 O75604 1/20 0.35
CYP2C9 P11712 2/20 0.35
CACNA2D1 P54289 2/20 0.35
CACNA1B Q00975 2/20 0.35
CACNB1 Q02641 2/20 0.35
CACNA1C Q13936 2/20 0.35
CACNA1G O43497 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1122107 0.83 SCN9A (0.47) SCN9ASCN7ASCN5AKMT2AMEN1
SCHEMBL3061976 0.74 KDM4E (0.31) LMNAUSP2
SCHEMBL9682608 0.72 CYP2D6 (0.45) SCN9ASCN7ASCN5ALMNACYP2D6
SCHEMBL1121748 0.72 SCN9A (0.40) SCN9ASCN7ASCN5AKMT2AMEN1
SCHEMBL24809013 0.72 CYP2D6 (0.46) SCN9ASCN7ASCN5AKMT2AMEN1
SCHEMBL1130577 0.69 SLC6A9 (0.43) SCN9ASCN7ASCN5AKMT2AMEN1
SCHEMBL85215 0.69 OPRM1 (0.44) SCN9ASCN7ASCN5AKMT2AMEN1
SCHEMBL85392 0.67 OPRM1 (0.48) KMT2AMEN1GAASLC6A9CYP2D6
SCHEMBL4106856 0.67 CCR5 (0.41)
SCHEMBL18641574 0.67 RBP4 (0.36) KMT2AMEN1LMNACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A SCN9A 395/4885SCN7A 376/4885SCN5A 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.